Please assess the completion status of the following clinical trial:

Trial Title: Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant patients who are treated with Lamivudine over 6 months (Considering include post kidney transplantation \> 6 months with stable calcineurin inhibitors level~2. Seropositive of HBsAg for 6 months~3. Willing and able to provide written informed consent~Exclusion Criteria:~1. Hepatitis cirrhosis patients~2. Co-infection with hepatitis C virus or HIV~3. Pregnant or nursing~4. YMDD resistant at baseline~5. ABO incompatible renal transplantation~6. Cross match positive~7. Poor renal function at baseline (eGFR\<20)~8. Known hypersensitivity or intolerance to any of the ingredients in Telbivudine~9. Known history of Telbivudine resistance

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lamivudine (Type: PLACEBO_COMPARATOR): HBsAg (+) patients received renal transplant and under lamivudine therapy.
- telbivudine (Type: ACTIVE_COMPARATOR): HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.

Based on this trial design, predict the completion outcome and termination type (if applicable).